APO Research
Talk to an analyst

APO RESEARCH · REPORT

Community-acquired Bacterial Pneumonia

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Community-acquired Bacterial Pneumonia Industry Growth and Trends Forecast to 2032

19 December 2025103 pages

Choose your research edition.

Industry ResearchCommunity-acquired Bacterial Pneumonia Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Community-acquired Bacterial Pneumonia Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Community-acquired Bacterial Pneumonia Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Community-acquired Bacterial Pneumonia Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Community-acquired Bacterial Pneumonia Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

According to APO Research, the global Community-acquired Bacterial Pneumonia market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Community-acquired Bacterial Pneumonia is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Community-acquired Bacterial Pneumonia is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Community-acquired Bacterial Pneumonia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Community-acquired Bacterial Pneumonia market include Takeda Pharmaceutical Company Limited, Sanofi S.A., Mylan N.V., Pfizer Inc., Bayer AG, Paratek Pharmaceuticals, Nabriva Therapeutics, Melinta Therapeutics and Lupin Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Community-acquired Bacterial Pneumonia market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Community-acquired Bacterial Pneumonia market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Community-acquired Bacterial Pneumonia market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Community-acquired Bacterial Pneumonia.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Community-acquired Bacterial Pneumonia market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Community-acquired Bacterial Pneumonia Market by Company

Takeda Pharmaceutical Company Limited

Sanofi S.A.

Mylan N.V.

Pfizer Inc.

Bayer AG

Paratek Pharmaceuticals

Nabriva Therapeutics

Melinta Therapeutics

Lupin Pharmaceuticals

Dainippon Sumitomo Pharma

Basilea Pharmaceutica International AG

Allergan plc

Community-acquired Bacterial Pneumonia Segment by Type

Oxazolidinone

Glycylcycline

Pleuromutilin Antibiotic

Ketolide

Cephalosporin

Others

Community-acquired Bacterial Pneumonia Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Community-acquired Bacterial Pneumonia Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Community-acquired Bacterial Pneumonia market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Community-acquired Bacterial Pneumonia and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Community-acquired Bacterial Pneumonia.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Community-acquired Bacterial Pneumonia companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Community-acquired Bacterial Pneumonia Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Community-acquired Bacterial Pneumonia Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Community-acquired Bacterial Pneumonia Market Share by Region (2021-2026) Table 4. Global Community-acquired Bacterial Pneumonia Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Community-acquired Bacterial Pneumonia Market Share by Region (2027-2032) Table 6. Global Community-acquired Bacterial Pneumonia Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Community-acquired Bacterial Pneumonia Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Community-acquired Bacterial Pneumonia Market Size Share by Type (2021-2026) Table 9. Global Community-acquired Bacterial Pneumonia Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Community-acquired Bacterial Pneumonia Market Size Share Forecasted by Type (2027-2032) Table 11. North America Community-acquired Bacterial Pneumonia Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Community-acquired Bacterial Pneumonia Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Community-acquired Bacterial Pneumonia Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Community-acquired Bacterial Pneumonia Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Community-acquired Bacterial Pneumonia Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Community-acquired Bacterial Pneumonia Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Community-acquired Bacterial Pneumonia Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Community-acquired Bacterial Pneumonia Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Community-acquired Bacterial Pneumonia Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Community-acquired Bacterial Pneumonia Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Community-acquired Bacterial Pneumonia Market Size Share by Application (2021-2026) Table 24. Global Community-acquired Bacterial Pneumonia Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Community-acquired Bacterial Pneumonia Market Size Share Forecasted by Application (2027-2032) Table 26. North America Community-acquired Bacterial Pneumonia Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Community-acquired Bacterial Pneumonia Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Community-acquired Bacterial Pneumonia Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Community-acquired Bacterial Pneumonia Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Community-acquired Bacterial Pneumonia Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Community-acquired Bacterial Pneumonia Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Community-acquired Bacterial Pneumonia Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Community-acquired Bacterial Pneumonia Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Community-acquired Bacterial Pneumonia Industry Trends Table 37. Community-acquired Bacterial Pneumonia Industry Drivers Table 38. Community-acquired Bacterial Pneumonia Industry Opportunities and Challenges Table 39. Community-acquired Bacterial Pneumonia Industry Restraints Table 40. Global Community-acquired Bacterial Pneumonia Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Company (2021-2026) Table 42. Global Community-acquired Bacterial Pneumonia Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Community-acquired Bacterial Pneumonia Key Company Headquarters & Area Served Table 44. Global Community-acquired Bacterial Pneumonia Company, Product Type & Application Table 45. Global Community-acquired Bacterial Pneumonia Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Community-acquired Bacterial Pneumonia by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Takeda Pharmaceutical Company Limited Company Information Table 49. Takeda Pharmaceutical Company Limited Business Overview Table 50. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product Portfolio Table 52. Takeda Pharmaceutical Company Limited Recent Development Table 53. Sanofi S.A. Company Information Table 54. Sanofi S.A. Business Overview Table 55. Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Sanofi S.A. Community-acquired Bacterial Pneumonia Product Portfolio Table 57. Sanofi S.A. Recent Development Table 58. Mylan N.V. Company Information Table 59. Mylan N.V. Business Overview Table 60. Mylan N.V. Community-acquired Bacterial Pneumonia Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Mylan N.V. Community-acquired Bacterial Pneumonia Product Portfolio Table 62. Mylan N.V. Recent Development Table 63. Pfizer Inc. Company Information Table 64. Pfizer Inc. Business Overview Table 65. Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Pfizer Inc. Community-acquired Bacterial Pneumonia Product Portfolio Table 67. Pfizer Inc. Recent Development Table 68. Bayer AG Company Information Table 69. Bayer AG Business Overview Table 70. Bayer AG Community-acquired Bacterial Pneumonia Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Bayer AG Community-acquired Bacterial Pneumonia Product Portfolio Table 72. Bayer AG Recent Development Table 73. Paratek Pharmaceuticals Company Information Table 74. Paratek Pharmaceuticals Business Overview Table 75. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio Table 77. Paratek Pharmaceuticals Recent Development Table 78. Nabriva Therapeutics Company Information Table 79. Nabriva Therapeutics Business Overview Table 80. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio Table 82. Nabriva Therapeutics Recent Development Table 83. Melinta Therapeutics Company Information Table 84. Melinta Therapeutics Business Overview Table 85. Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio Table 87. Melinta Therapeutics Recent Development Table 88. Lupin Pharmaceuticals Company Information Table 89. Lupin Pharmaceuticals Business Overview Table 90. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio Table 92. Lupin Pharmaceuticals Recent Development Table 93. Dainippon Sumitomo Pharma Company Information Table 94. Dainippon Sumitomo Pharma Business Overview Table 95. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product Portfolio Table 97. Dainippon Sumitomo Pharma Recent Development Table 98. Basilea Pharmaceutica International AG Company Information Table 99. Basilea Pharmaceutica International AG Business Overview Table 100. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product Portfolio Table 102. Basilea Pharmaceutica International AG Recent Development Table 103. Allergan plc Company Information Table 104. Allergan plc Business Overview Table 105. Allergan plc Community-acquired Bacterial Pneumonia Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Allergan plc Community-acquired Bacterial Pneumonia Product Portfolio Table 107. Allergan plc Recent Development Table 108. North America Community-acquired Bacterial Pneumonia Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. North America Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026) & (US$ Million) Table 110. North America Community-acquired Bacterial Pneumonia Market Share by Country (2021-2026) Table 111. North America Community-acquired Bacterial Pneumonia Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. North America Community-acquired Bacterial Pneumonia Market Share Forecast by Country (2027-2032) Table 113. Europe Community-acquired Bacterial Pneumonia Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Europe Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026) & (US$ Million) Table 115. Europe Community-acquired Bacterial Pneumonia Market Share by Country (2021-2026) Table 116. Europe Community-acquired Bacterial Pneumonia Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Europe Community-acquired Bacterial Pneumonia Market Share Forecast by Country (2027-2032) Table 118. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026) & (US$ Million) Table 120. Asia-Pacific Community-acquired Bacterial Pneumonia Market Share by Country (2021-2026) Table 121. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Asia-Pacific Community-acquired Bacterial Pneumonia Market Share Forecast by Country (2027-2032) Table 123. Latin America Community-acquired Bacterial Pneumonia Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026) & (US$ Million) Table 125. Latin America Community-acquired Bacterial Pneumonia Market Share by Country (2021-2026) Table 126. Latin America Community-acquired Bacterial Pneumonia Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Latin America Community-acquired Bacterial Pneumonia Market Share Forecast by Country (2027-2032) Table 128. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026) & (US$ Million) Table 130. Middle East & Africa Community-acquired Bacterial Pneumonia Market Share by Country (2021-2026) Table 131. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Middle East & Africa Community-acquired Bacterial Pneumonia Market Share Forecast by Country (2027-2032) Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Community-acquired Bacterial Pneumonia Product Image Figure 3. Global Community-acquired Bacterial Pneumonia Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 5. Global Community-acquired Bacterial Pneumonia Market Share by Region: 2025 VS 2032 Figure 6. Global Community-acquired Bacterial Pneumonia Market Share by Region (2021-2032) Figure 7. North America Community-acquired Bacterial Pneumonia Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Community-acquired Bacterial Pneumonia Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Community-acquired Bacterial Pneumonia Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Oxazolidinone Image Figure 13. Global Oxazolidinone Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Glycylcycline Image Figure 15. Global Glycylcycline Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Pleuromutilin Antibiotic Image Figure 17. Global Pleuromutilin Antibiotic Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Ketolide Image Figure 19. Global Ketolide Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Cephalosporin Image Figure 21. Global Cephalosporin Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Others Image Figure 23. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Global Community-acquired Bacterial Pneumonia Market Size Overview by Type (2021-2032) & (US$ Million) Figure 25. Global Community-acquired Bacterial Pneumonia Market Share by Type 2025 VS 2032 Figure 26. North America Community-acquired Bacterial Pneumonia Market Size Share by Type (2021-2032) Figure 27. Europe Community-acquired Bacterial Pneumonia Market Size Share by Type (2021-2032) Figure 28. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Share by Type (2021-2032) Figure 29. Latin America Community-acquired Bacterial Pneumonia Market Size Share by Type (2021-2032) Figure 30. Middle East and Africa Community-acquired Bacterial Pneumonia Market Size Share by Type (2021-2032) Figure 31. Retail Pharmacies Image Figure 32. Global Retail Pharmacies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Online Pharmacies Image Figure 34. Global Online Pharmacies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Hospital Pharmacies Image Figure 36. Global Hospital Pharmacies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Global Community-acquired Bacterial Pneumonia Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Community-acquired Bacterial Pneumonia Market Share by Application 2025 VS 2032 Figure 39. North America Community-acquired Bacterial Pneumonia Market Size Share by Application (2021-2032) Figure 40. Europe Community-acquired Bacterial Pneumonia Market Size Share by Application (2021-2032) Figure 41. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Share by Application (2021-2032) Figure 42. Latin America Community-acquired Bacterial Pneumonia Market Size Share by Application (2021-2032) Figure 43. Middle East and Africa Community-acquired Bacterial Pneumonia Market Size Share by Application (2021-2032) Figure 44. Global Top 5 and 10 Community-acquired Bacterial Pneumonia Players Market Share by Revenue in 2025 Figure 45. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 46. North America Community-acquired Bacterial Pneumonia Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. North America Community-acquired Bacterial Pneumonia Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. North America Community-acquired Bacterial Pneumonia Market Share by Country (2021-2032) Figure 49. Europe Community-acquired Bacterial Pneumonia Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Community-acquired Bacterial Pneumonia Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Community-acquired Bacterial Pneumonia Market Share by Country (2021-2032) Figure 52. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Asia-Pacific Community-acquired Bacterial Pneumonia Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Asia-Pacific Community-acquired Bacterial Pneumonia Market Share by Country (2021-2032) Figure 55. Latin America Community-acquired Bacterial Pneumonia Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Community-acquired Bacterial Pneumonia Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Community-acquired Bacterial Pneumonia Market Share by Country (2021-2032) Figure 58. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Middle East & Africa Community-acquired Bacterial Pneumonia Market Share by Country: 2021 VS 2025 VS 2032 Figure 60. Middle East & Africa Community-acquired Bacterial Pneumonia Market Share by Country (2021-2032) Figure 61. Years Considered Figure 62. Research Process Figure 63. Key Executives Interviewed

Scope & coverage.

Types
  • Oxazolidinone
  • Glycylcycline
  • Pleuromutilin Antibiotic
  • Ketolide
  • Cephalosporin
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.
  • Mylan N.V.
  • Pfizer Inc.
  • Bayer AG
  • Paratek Pharmaceuticals
  • Nabriva Therapeutics
  • Melinta Therapeutics
  • Lupin Pharmaceuticals
  • Dainippon Sumitomo Pharma
  • Basilea Pharmaceutica International AG
  • Allergan plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Community-acquired Bacterial Pneumonia Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Community-acquired Bacterial Pneumonia Market Size by Region (2021-2032)
  5. 1.4.1 Global Community-acquired Bacterial Pneumonia Market Size by Region (2021-2026)
  6. 1.4.2 Global Community-acquired Bacterial Pneumonia Market Size by Region (2027-2032)
  7. 1.5 Key Regions Community-acquired Bacterial Pneumonia Market Size (2021-2032)
  8. 1.5.1 North America Community-acquired Bacterial Pneumonia Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Community-acquired Bacterial Pneumonia Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Community-acquired Bacterial Pneumonia Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Growth Rate (2021-2032)
2 Community-acquired Bacterial Pneumonia Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Oxazolidinone
  3. 2.1.2 Glycylcycline
  4. 2.1.3 Pleuromutilin Antibiotic
  5. 2.1.4 Ketolide
  6. 2.1.5 Cephalosporin
  7. 2.1.6 Others
  8. 2.2 Global Community-acquired Bacterial Pneumonia Market Size by Type
  9. 2.2.1 Global Community-acquired Bacterial Pneumonia Market Size Overview by Type (2021-2032)
  10. 2.2.2 Global Community-acquired Bacterial Pneumonia Historic Market Size Review by Type (2021-2026)
  11. 2.2.3 Global Community-acquired Bacterial Pneumonia Market Size Forecasted by Type (2027-2032)
  12. 2.3 Global Community-acquired Bacterial Pneumonia Market Size by Regions
  13. 2.3.1 North America Community-acquired Bacterial Pneumonia Market Size Breakdown by Type (2021-2026)
  14. 2.3.2 Europe Community-acquired Bacterial Pneumonia Market Size Breakdown by Type (2021-2026)
  15. 2.3.3 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Breakdown by Type (2021-2026)
  16. 2.3.4 South America Community-acquired Bacterial Pneumonia Market Size Breakdown by Type (2021-2026)
  17. 2.3.5 Middle East and Africa Community-acquired Bacterial Pneumonia Market Size Breakdown by Type (2021-2026)
3 Community-acquired Bacterial Pneumonia Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Retail Pharmacies
  3. 3.1.2 Online Pharmacies
  4. 3.1.3 Hospital Pharmacies
  5. 3.2 Global Community-acquired Bacterial Pneumonia Market Size by Application
  6. 3.2.1 Global Community-acquired Bacterial Pneumonia Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Community-acquired Bacterial Pneumonia Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Community-acquired Bacterial Pneumonia Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Community-acquired Bacterial Pneumonia Market Size by Regions
  10. 3.3.1 North America Community-acquired Bacterial Pneumonia Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Community-acquired Bacterial Pneumonia Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Community-acquired Bacterial Pneumonia Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Community-acquired Bacterial Pneumonia Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Community-acquired Bacterial Pneumonia Industry Trends
  2. 4.2 Community-acquired Bacterial Pneumonia Industry Drivers
  3. 4.3 Community-acquired Bacterial Pneumonia Industry Opportunities and Challenges
  4. 4.4 Community-acquired Bacterial Pneumonia Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Community-acquired Bacterial Pneumonia Revenue (2021-2026)
  2. 5.2 Global Community-acquired Bacterial Pneumonia Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Community-acquired Bacterial Pneumonia Key Company Headquarters & Area Served
  4. 5.4 Global Community-acquired Bacterial Pneumonia Company, Product Type & Application
  5. 5.5 Global Community-acquired Bacterial Pneumonia Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Community-acquired Bacterial Pneumonia Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Community-acquired Bacterial Pneumonia Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Community-acquired Bacterial Pneumonia Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Takeda Pharmaceutical Company Limited
  2. 6.1.1 Takeda Pharmaceutical Company Limited Company Information
  3. 6.1.2 Takeda Pharmaceutical Company Limited Business Overview
  4. 6.1.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product Portfolio
  6. 6.1.5 Takeda Pharmaceutical Company Limited Recent Developments
  7. 6.2 Sanofi S.A.
  8. 6.2.1 Sanofi S.A. Company Information
  9. 6.2.2 Sanofi S.A. Business Overview
  10. 6.2.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi S.A. Community-acquired Bacterial Pneumonia Product Portfolio
  12. 6.2.5 Sanofi S.A. Recent Developments
  13. 6.3 Mylan N.V.
  14. 6.3.1 Mylan N.V. Company Information
  15. 6.3.2 Mylan N.V. Business Overview
  16. 6.3.3 Mylan N.V. Community-acquired Bacterial Pneumonia Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Mylan N.V. Community-acquired Bacterial Pneumonia Product Portfolio
  18. 6.3.5 Mylan N.V. Recent Developments
  19. 6.4 Pfizer Inc.
  20. 6.4.1 Pfizer Inc. Company Information
  21. 6.4.2 Pfizer Inc. Business Overview
  22. 6.4.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Pfizer Inc. Community-acquired Bacterial Pneumonia Product Portfolio
  24. 6.4.5 Pfizer Inc. Recent Developments
  25. 6.5 Bayer AG
  26. 6.5.1 Bayer AG Company Information
  27. 6.5.2 Bayer AG Business Overview
  28. 6.5.3 Bayer AG Community-acquired Bacterial Pneumonia Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Bayer AG Community-acquired Bacterial Pneumonia Product Portfolio
  30. 6.5.5 Bayer AG Recent Developments
  31. 6.6 Paratek Pharmaceuticals
  32. 6.6.1 Paratek Pharmaceuticals Company Information
  33. 6.6.2 Paratek Pharmaceuticals Business Overview
  34. 6.6.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio
  36. 6.6.5 Paratek Pharmaceuticals Recent Developments
  37. 6.7 Nabriva Therapeutics
  38. 6.7.1 Nabriva Therapeutics Company Information
  39. 6.7.2 Nabriva Therapeutics Business Overview
  40. 6.7.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio
  42. 6.7.5 Nabriva Therapeutics Recent Developments
  43. 6.8 Melinta Therapeutics
  44. 6.8.1 Melinta Therapeutics Company Information
  45. 6.8.2 Melinta Therapeutics Business Overview
  46. 6.8.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Melinta Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio
  48. 6.8.5 Melinta Therapeutics Recent Developments
  49. 6.9 Lupin Pharmaceuticals
  50. 6.9.1 Lupin Pharmaceuticals Company Information
  51. 6.9.2 Lupin Pharmaceuticals Business Overview
  52. 6.9.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio
  54. 6.9.5 Lupin Pharmaceuticals Recent Developments
  55. 6.10 Dainippon Sumitomo Pharma
  56. 6.10.1 Dainippon Sumitomo Pharma Company Information
  57. 6.10.2 Dainippon Sumitomo Pharma Business Overview
  58. 6.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product Portfolio
  60. 6.10.5 Dainippon Sumitomo Pharma Recent Developments
  61. 6.11 Basilea Pharmaceutica International AG
  62. 6.11.1 Basilea Pharmaceutica International AG Company Information
  63. 6.11.2 Basilea Pharmaceutica International AG Business Overview
  64. 6.11.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product Portfolio
  66. 6.11.5 Basilea Pharmaceutica International AG Recent Developments
  67. 6.12 Allergan plc
  68. 6.12.1 Allergan plc Company Information
  69. 6.12.2 Allergan plc Business Overview
  70. 6.12.3 Allergan plc Community-acquired Bacterial Pneumonia Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Allergan plc Community-acquired Bacterial Pneumonia Product Portfolio
  72. 6.12.5 Allergan plc Recent Developments
7 North America
  1. 7.1 North America Community-acquired Bacterial Pneumonia Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026)
  3. 7.3 North America Community-acquired Bacterial Pneumonia Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Community-acquired Bacterial Pneumonia Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026)
  3. 8.3 Europe Community-acquired Bacterial Pneumonia Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Community-acquired Bacterial Pneumonia Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026)
  3. 10.3 South America Community-acquired Bacterial Pneumonia Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst